Compare Elastic NV (ESTC) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Smith & Nephew plc — how do they compare? Elastic NV trades at $61.54 (market cap $6.47B), while Smith & Nephew plc trades at $31.22 (market cap $12.81B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.54% dividend while Elastic NV pays none. Which is the better fit depends on your goals.
| ESTC | SNN | |
|---|---|---|
Market Cap | $6.47B | $12.81B |
Sector | Technology | Health |
52-Week High | $94.47 | $38.70 |
52-Week Low | $43.30 | $28.73 |
Enterprise Value | $5.69B | $15.58B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic N.V. (ESTC) trades at $61.75, down 0.91% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust revenue growth, reaching $1.48B in 2025 with expectations of $1.7B in 2026, and has consistently beaten EPS estimates in recent quarters. Recent positive news includes Elastic Security achieving a 100% malware protection score and being named a Leader in IDC MarketScape's SIEM 2026 assessment.
Wall Street maintains a bullish outlook with 23 buy ratings and a $73 consensus price target, representing 18% upside. However, investors should note the high EV/EBITDA ratio of 164.13 and ongoing legal investigations highlighted in recent news. The stock's current RSI levels suggest potential overbought conditions, while strong profitability metrics and institutional support provide fundamental backing.
Smith & Nephew (SNN) trades at $29.83, down 4.02% today, with a bearish technical signal. The company reported revenue of $5.81 billion in 2024, with net income of $412 million, showing improved profitability. Recent news highlights product launches in robotics and wound care, supported by a $500 million share buyback. Analyst consensus is mixed, with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility.
Outlook is balanced: strong free cash flow and innovation in medical technology offer growth potential, but near-term risks include competitive pressures and debt levels. The stock's valuation at a P/E of 21.51 is reasonable if earnings growth sustains, yet technical weakness suggests caution. Investors should weigh solid fundamentals against market sentiment and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
